blincyto
NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population
June 19, 2019Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma
Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …
Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia
January 23, 2019Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma
The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …
Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients
September 2, 2016Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia
Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
Novartis and Amgen drugs signed-off by European Commission
November 24, 2015Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto
The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …
Speedy FDA nod for Amgen leukaemia drug
December 5, 2014Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia
The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …
